Confronto
Elamipretide vs. Melanotan II
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
736992-21-5
121062-08-6
Peso molecolare
639.8 g/mol
1024.18 g/mol
Emivita
nessun dato
1 h
Sequenza
D-Arg-Dmt-Lys-Phe-NH2Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2Meccanismo d'azione
Elamipretide
Elamipretide is a cell-permeable tetrapeptide with alternating aromatic and basic residues that selectively concentrates on cardiolipin — a phospholipid found almost exclusively in the inner mitochondrial membrane that is important for cristae curvature and the organisation of the respiratory-chain complexes. By binding cardiolipin, elamipretide is proposed to stabilise cristae architecture, support electron transport and ATP production, and reduce the formation of reactive oxygen species. These mechanistic models derive largely from cell and animal models and biophysical work; the extent to which they explain clinical efficacy in humans is, given the mixed trial results, a matter of ongoing research.
Melanotan II
Melanotan II binds non-selectively to all five melanocortin-receptor subtypes (MC1R-MC5R). Via MC1R in melanocytes, eumelanin synthesis is stimulated (pigmenting effect). Via MC4R and MC3R in the CNS, appetite, sexual function and blood pressure are modulated. The cyclic structure and D-amino acids increase stability compared to natural α-MSH.
Base di evidenze
Evidenza più alta
RCT sull'uomo
Studio sull'uomo
Studi
4
9
di cui sull'uomo
4
5
Effetti registrati
4
4
Contraddizioni aperte
1
1
Eventi avversi documentati
1
6
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Elamipretide and Melanotan II?
- Elamipretide is classified as "Ricerca (altro)", while Melanotan II is classified as "Ricerca (altro)". Elamipretide: Elamipretide (SS-31, MTP-131, formerly Bendavia) is a synthetic, mitochondria-targeting tetrapeptide (sequence D-Arg-Dmt-Lys-Phe-NH2) that binds cardiolipin on the inner mitochondrial membrane and is proposed to stabilise cristae structure and support mitochondrial bioenergetics. It was investigated clinically by Stealth BioTherapeutics across several indications, including primary mitochondrial myopathy, Barth syndrome, heart failure, and dry age-related macular degeneration (geographic atrophy). The trial record is mixed, with several pivotal studies missing their primary endpoints. In September 2025 elamipretide (brand name Forzinity) received accelerated FDA approval in the United States solely for the ultra-rare Barth syndrome; for all other investigated indications it remains investigational and it is not approved as a medicine outside the United States. Melanotan II: Cyclic hepta-peptide and non-selective melanocortin-receptor agonist. Originally researched at the University of Arizona as a sun-protection concept — never approved as a medicine. Widespread on the black market; regulatory warnings for cardiovascular and oncological risks. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Elamipretide or Melanotan II?
- The highest available evidence level is "RCT sull'uomo" for Elamipretide and "Studio sull'uomo" for Melanotan II. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Elamipretide and Melanotan II in Germany and the United States?
- Germania: Elamipretide — Non approvato, Melanotan II — Non approvato. Stati Uniti: Elamipretide — Su prescrizione, Melanotan II — Non approvato. These are factual summaries with source and review date on the individual pages.